-+ 0.00%
-+ 0.00%
-+ 0.00%

Trinity Innovation leads angel round in Navi Therapeutics, which later closes A round worth several hundred million yuan

PUBT·08/18/2026 09:10:51
Listen to the news
Trinity Innovation leads angel round in Navi Therapeutics, which later closes A round worth several hundred million yuan
  • Navi Therapeutics, a Shanghai-based biotech, closed a Series A round, lifting total funding across angel and Series A rounds to several hundred million CNY.
  • Trinity Innovation Beijing Investment Management led the angel round; Yuanhe Yuandian, Fenglei Capital participated; all angel investors followed on in Series A.
  • Series A was led by Legend Capital; Kangjun Capital co-led; additional investors included Oriza Seed and strategic backers.
  • Navi develops AI-driven antibody-drug conjugates for solid tumors; it plans to file its first IND applications in 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Innovation Beijing Investment Management Co Ltd published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.